June 11, 2017 / 3:57 PM / a month ago

Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials

1 Min Read

PARIS (Reuters) - France's Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.

Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.

Reporting by Laurence Frost; Editing by Mark Potter

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below